Blog

Contains articles from Dante and our partners discussing the latest research, publications, and updates about genome sequencing.
Dante Genomics launches doctor ordered, clinical whole genome sequencing in the U.S. in partnership with 1health.io
About Us

Dante Genomics launches doctor ordered, clinical whole genome sequencing in the U.S. in partnership with 1health.io

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Read More ➝
Dante Genomics partnership with Al Farabi Medical Laboratories
About Us

Al Farabi Medical Laboratories and Dante Genomics announce global partnership for the delivery of Next Generation Sequencing Genomic Testing in the Kingdom of Saudi Arabia

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Read More ➝
Dante Genomics will participate in The Canaccord Genuity MedTech Diagnostics and Digital Health and Services Forum 2022.
About Us

Dante Genomics to present at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Read More ➝
Longenesis Partners with Dante Genomics to Offer Whole Genome Sequencing
About Us

Longenesis Partners with Dante Genomics to Offer Whole Genome Sequencing Solutions for Women’s Health in Europe

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Read More ➝
Genomic Biopharma Inc logo
About Us

Dante Genomics creates separate drug discovery and development company Genomic Biopharma Inc.

Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.

Read More ➝
About Us

Dante Genomics Unveils Digital Health Population Genomics Program at the United Nations General Assembly Science Summit

 Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.

Read More ➝
dante genomics dna sequencing
Diagnostics

TMA Precision Health and Dante Genomics partner to help children with rare diseases through clinical whole genome sequencing solutions

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Read More ➝
Rate device for blood sampling kit
About Us

Dante Genomics to innovate universal genomics by now offering easy, at-home blood collection kits for clinical whole genome sequencing without the use of a needle

Dante Genomics, a global leader in genomics and precision medicine, today announced that members of its management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, and Andrea Riposati, CEO of Dante Genomics, will participate in a panel presentation on leveraging omics-based data and analytics to advance precision health to the next level on Thursday, August 11, 2022 at 9:30 AM Eastern Time.

Read More ➝
Dante Genomics will participate in The Canaccord Genuity 42nd Annual Growth Conference 2022.
About Us

Dante Genomics to Participate in a Panel Presentation at the Canaccord Genuity 42nd Annual Growth Conference

Dante Genomics, a global leader in genomics and precision medicine, today announced that members of its management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, and Andrea Riposati, CEO of Dante Genomics, will participate in a panel presentation on leveraging omics-based data and analytics to advance precision health to the next level on Thursday, August 11, 2022 at 9:30 AM Eastern Time.

Read More ➝